Figure 1. TAK1 is required for doxorubicin (Dox) induced NF-κB, p38 and JNK activation.

(A) TAK1^+/+ and TAK1^−/− MEFs were treated with Dox at the indicated time points or left untreated, protein extracts were subjected to SDS-PAGE and immunoblotted with antibodies indicated. (B) TAK1-deficient and TAK1 wildtype reconstituted MEF cells were treated with Dox at the indicated time points or left untreated, protein extracts were subjected to SDS-PAGE and immunoblotted with antibodies indicated. (C) TAK1^+/+ and TAK1^−/− MEFs were treated with VP-16 at the indicated time points or left untreated, protein extracts were subjected to SDS-PAGE and immunoblotted with antibodies indicated. (D) TAK1^+/+ and TAK1^−/− MEFs were treated with CPT at the indicated time points or left untreated, protein extracts were subjected to SDS-PAGE and immunoblotted with antibodies indicated. (E) TAK1^+/+ and TAK1^−/− MEFs were treated with ionizing radiation (IR) at the indicated dose or left untreated, protein extracts were subjected to SDS-PAGE and immunoblotted with antibodies indicated. β-actin was detected as a loading control for whole cell extracts.